Sesen Bio, Inc. (SESN) News
Filter SESN News Items
SESN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SESN News From Around the Web
Below are the latest news stories about Sesen Bio Inc that investors may wish to consider to help them evaluate SESN as an investment opportunity.
Sesen Bio: Q4 Earnings InsightsSesen Bio (NASDAQ: SESN ) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Sesen Bio beat estimated earnings by 157.14%, reporting … Full story available on Benzinga.com |
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Company |
Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Sesen Bio Further Enhances Team with Key HiresCAMBRIDGE, Mass., January 10, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022. |
Lifshitz Law Firm, P.C. Announces Investigations of Generac Holdings Inc. (NYSE: GNRC), Katapult Holdings, Inc. (NASDAQGM: KPLT), PayPal Holdings, Inc. (NASDAQGS: PYPL), and SeSen Bio, Inc. (NASDAQGM: SESN)NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Generac Holdings Inc. (NYSE: GNRC) |
6 of the Best Penny Stocks Under $1 to Buy Now for 2022These penny stocks trading for under $1 per share all have strong chances of delivering stunning returns in the coming year. |
Sesen Bio Inc. (NASDAQ: SESN)s Gain Of 1.99% Profited InvestorsSesen Bio Inc. (NASDAQ:SESN) traded at $0.89 at close of the session on Tuesday, 12/21/21, made an upward move of 1.99% on its previous days price. Looking at the stock we see that its previous close was $0.87 and the beta (5Y monthly) reads 0.50 with the days price range being $0.8525 $0.9008. In Sesen Bio Inc. (NASDAQ: SESN)s Gain Of 1.99% Profited Investors Read More » |
Zacks: Brokerages Anticipate Sesen Bio, Inc. (NASDAQ:SESN) to Post -$0.08 Earnings Per ShareEquities research analysts forecast that Sesen Bio, Inc. (NASDAQ:SESN) will report ($0.08) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sesen Bios earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.10). Sesen Bio posted earnings per share of ($0.07) during [] |
Sesen Bio Inc. (SESN) Has Recovered 21.35% From Its Low: Is This The Beginning Of A Trend?Sesen Bio Inc. (NASDAQ:SESN) price on Friday, December 10, fall -0.16% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.89. A look at the stocks price movement, the level at last check in todays session was $0.89, moving within a range at $0.8399 and $0.9499. The beta Sesen Bio Inc. (SESN) Has Recovered 21.35% From Its Low: Is This The Beginning Of A Trend? Read More » |
Why Sesen Bio Stock Got Slammed TodayThe biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). In its press release published just after the meeting, which Sesen Bio characterized as "productive," the company wrote that it now "believes it has greater clarity regarding the requirements for resubmission of the BLA and the trial design." |